# VTGN earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/VTGN) · [Earnings tab](https://www.lopjlb.com/stock/VTGN?tab=earnings)

Updated: 2026-11-12T06:47:37

Quarters analyzed: 8

## Cross-quarter narrative

Across eight quarterly CallCards, VistaGen’s pipeline has moved from reporting a single positive Phase 3 result (PALISADE‑2) to managing multiple late‑stage programs. The fasedienol PALISADE‑3 and PALISADE‑4 trials remain on track, with top‑line data expected in late 2025 and a tentative NDA filing in H1 2026. Parallel programs—itruvone for MDD, PH80 for menopausal hot flashes and other women’s‑health indications, and a repeat‑dose study prompted by the FDA—have progressed from planning to active execution. Cash balances have fallen from $119 M to $63 M while net losses have widened, sharpening financing concerns. Management tone, initially upbeat, has drifted lower as execution challenges (site termination, stringent eligibility) and regulatory uncertainty surface. Recurrent fears—clinical replication risk, regulatory ambiguity, competitive pressure, and cash runway—persist, with new operational risks emerging in 2026. Despite these headwinds, the company maintains a clear clinical roadmap, but financial pressure and execution variability increasingly dominate the narrative.

## Latest CallCard · Q3

**Guidance:** vague

**Tone:** mgmt 0 · Q&A pressure 0 · divergence 0

## Quarter one-liners

- **2026 Q3:** —
- **2026 Q2:** VistaGen completed PALISADE 3 enrollment, expects top-line results by year-end 2025, targets NDA submission ~2026 if positive; $77.2M cash covers program; advancing itravone and PH80.','tone': {'mgmt': 0.7, 'mgmt_rationale': 'Management emphasizes strong momentum, transformative period, deep confide
- **2026 Q1:** Vistagen advances PALISADE-3/4 Phase III trials for fasedienol in SAD; Q4 2025 top-line data expected, $63.2M cash, PH80 IND planned Q4.
- **2025 Q4:** Vistagen reports FY25 results, advances 5 intranasal pherine candidates; fasedienol Phase III PALISADE-3 top-line Q4 2025, PALISADE-4 H1 2026; PH80 IND H2 2025; cash $80.5M. Net loss $51.4M, R&D $39.4M. FDA engagement positive but regulatory uncertainty remains. Strong patient demand offset by strin
- **2025 Q3:** VistaGen advances five intranasal pherine candidates; Palisade 3/4 Phase 3 for fasedienol in SAD on track for 2025 data; cash $88.6M; repeat-dose study initiated per FDA request. R&D spend rising. No financial guidance.
- **2025 Q2:** Vistagen advances fasedienol Phase 3 SAD trials (PALISADE-3/4) on track for 2025 readouts, prepares itruvone Phase 2b MDD protocol, and targets PH80 IND submission in Q2 2025 with $97.6M cash.','tone': {'mgmt': 0.6, 'mgmt_rationale': 'CEO emphasizes pipeline progress, on-track timelines, PI exciteme
- **2025 Q1:** Vistagen advances PALISADE-3/4 Phase 3 for Fasedienol in SAD (on track, readouts 2025), preps Itruvone Phase 2b for MDD (protocol to FDA by year-end), and PH80 IND-enabling work; $108M cash. No revenue; R&D/G&A rising. Majority capital to PALISADE program. Key risks: Phase 3 replication, FDA adminis
- **2024 Q4:** Vistagen reports positive PALISADE-2 Phase 3 results for fasedienol in SAD, launches PALISADE-3, plans PALISADE-4 and repeat-dose study, targets NDA submission H1 2026, with $119M cash.

## Theme arcs

- **clinical development progression** (improving): Multiple Phase 3 programs advanced; NDA preparation initiated
- **financial position** (deteriorating): Cash fell from $119M to $63M; net loss grew to $51M
- **management confidence** (deteriorating): Tone scores dropped from 0.80 to 0.00 in later calls
- **regulatory risk** (stable): Ongoing uncertainty, Fast‑Track designation, FDA requests for repeat‑dose study
- **competitive landscape** (deteriorating): New competitors (Neuforia) noted, market pressure acknowledged
- **operational execution risk** (new): Site termination in Pennsylvania and enrollment slow‑downs surfaced in 2026 Q1

## Guidance path

2024 Q4:maintained → 2025 Q1:vague → 2025 Q2:vague → 2025 Q3:maintained → 2025 Q4:vague → 2026 Q1:maintained → 2026 Q2:vague → 2026 Q3:vague

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/VTGN`